Interferon alpha subtype-specific suppression of HIV-1 infection in vivo

Journal of Virology

Volumn 90, Issue 13, 2016, Pages 6001-6013

  Lavender, Kerry J ^a   Gibbert, Kathrin ^b   Peterson, Karin E ^a   Van Dis, Erik ^a   Francois, Sandra ^b   Woods, Tyson ^a   Messer, Ronald J ^a   Gawanbacht, Ali ^c   Müller, Janis A ^c   Münch, Jan ^c   Phillips, Katie ^a   Race, Brent ^a   Harper, Michael S ^f   Guo, Kejun ^f   Lee, Eric J ^f   Trilling, Mirko ^b   Hengel, Hartmut ^d   Piehler, Jacob ^e   Verheyen, Jens ^b   Wilson, Cara C ^f   Santiago, Mario L ^f   Hasenkrug, Kim J ^a   Dittmer, Ulf ^b   more..

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF OSNABRÜCK   (Germany)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA14 INTERFERON; ALPHA2 INTERFERON; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MX2 PROTEIN; PROTEIN; TETHERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VIRUS DNA; ANTIVIRUS AGENT; APOBEC3G PROTEIN, HUMAN; BST2 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN; MX2 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; INNATE IMMUNITY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; CLASSIFICATION; DISEASE COURSE; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; TRANSGENIC MOUSE; VIROLOGY;

ANIMALS; ANTIGENS, CD; ANTIVIRAL AGENTS; APOBEC-3G DEAMINASE; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; GPI-LINKED PROTEINS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; INTERFERON-ALPHA; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; MYXOVIRUS RESISTANCE PROTEINS; VIRAL LOAD; VIREMIA; VIRUS REPLICATION;

EID: 84975251680     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00451-16     Document Type: Article

References (86)

1. Hardy MP, Owczarek CM, Jermiin LS, Ejdeback M, Hertzog PJ. 2004. Characterization of the type I interferon locus and identification of novel genes. Genomics 84:331-345. http://dx.doi.org/10.1016/j.ygeno.2004.03.003.
2. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, Lee C, Yarden G, Vleck SE, Glenn JS, Nolan GP, Piehler J, Schreiber G, Garcia KC. 2011. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 146:621-632. http://dx.doi.org/10.1016/j.cell.2011.06.048.
3. Jaks E, Gavutis M, Uze G, Martal J, Piehler J. 2007. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 366:525-539. http://dx.doi.org/10.1016/j.jmb.2006.11.053.
4. Lavoie TB, Kalie E, Crisafulli-Cabatu S, Abramovich R, DiGioia G, Moolchan K, Pestka S, Schreiber G. 2011. Binding and activity of all human alpha interferon subtypes. Cytokine 56:282-289. http://dx.doi.org/10.1016/j.cyto.2011.07.019.
5. Cull VS, Tilbrook PA, Bartlett EJ, Brekalo NL, James CM. 2003. Type I interferon differential therapy for erythroleukemia: specificity of STAT activation. Blood 101:2727-2735. http://dx.doi.org/10.1182/blood-2002-05-1521.
6. Manry J, Laval G, Patin E, Fornarino S, Itan Y, Fumagalli M, Sironi M, Tichit M, Bouchier C, Casanova JL, Barreiro LB, Quintana-Murci L. 2011. Evolutionary genetic dissection of human interferons. J Exp Med 208:2747-2759. http://dx.doi.org/10.1084/jem.20111680.
7. Gerlach N, Gibbert K, Alter C, Nair S, Zelinskyy G, James CM, Dittmer U. 2009. Anti-retroviral effects of type I IFN subtypes in vivo. Eur J Immunol 39:136-146. http://dx.doi.org/10.1002/eji.200838311.
8. Gibbert K, Joedicke JJ, Meryk A, Trilling M, Francois S, Duppach J, Kraft A, Lang KS, Dittmer U. 2012. Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection. PLoS Pathog 8:e1002868. http://dx.doi.org/10.1371/journal.ppat.1002868.
9. Austin BA, James C, Silverman RH, Carr DJ. 2005. Critical role for the oligoadenylate synthetase/RNase L pathway in response to IFN-beta during acute ocular herpes simplex virus type 1 infection. J Immunol 175: 1100-1106. http://dx.doi.org/10.4049/jimmunol.175.2.1100.
10. Austin BA, James CM, Harle P, Carr DJ. 2006. Direct application of plasmid DNA containing type I interferon transgenes to vaginal mucosa inhibits HSV-2 mediated mortality. Biol Proced Online 8:55-62. http://dx.doi.org/10.1251/bpo118.
11. James CM, Abdad MY, Mansfield JP, Jacobsen HK, Vind AR, Stumbles PA, Bartlett EJ. 2007. Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein. Vaccine 25:1856-1867. http://dx.doi.org/10.1016/j.vaccine.2006.10.038.
12. Tsang SL, Leung PC, Leung KK, Yau WL, Hardy MP, Mak NK, Leung KN, Fung MC. 2007. Characterization of murine interferon-alpha 12 (MuIFN-alpha12): biological activities and gene expression. Cytokine 37: 138-149. http://dx.doi.org/10.1016/j.cyto.2007.03.002.
13. Yeow WS, Lai CM, Beilharz MW. 1997. The in vivo expression patterns of individual type I interferon genes in murine cytomegalovirus infections. Antiviral Res 34:17-26. http://dx.doi.org/10.1016/S0166-3542(96)01018-2.
14. Harper MS, Guo K, Gibbert K, Lee EJ, Dillon SM, Barrett BS, McCarter MD, Hasenkrug KJ, Dittmer U, Wilson CC, Santiago ML. 2015. Interferon-alpha subtypes in an ex vivo model of acute HIV-1 infection: expression, potency and effector mechanisms. PLoS Pathog 11:e1005254. http://dx.doi.org/10.1371/journal.ppat.1005254.
15. Yan N, Chen ZJ. 2012. Intrinsic antiviral immunity. Nat Immunol 13: 214-222. http://dx.doi.org/10.1038/ni.2229.
16. Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, Yukl S, Greene WC, Kovari H, Rauch A, Fellay J, Battegay M, Hirschel B, Witteck A, Bernasconi E, Ledergerber B, Gunthard HF, Wong JK, Swiss HIV Cohort Study. 2012. Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci U S A 109:3035-3040. http://dx.doi.org/10.1073/pnas.1111573109.
17. Kane M, Yadav SS, Bitzegeio J, Kutluay SB, Zang T, Wilson SJ, Schoggins JW, Rice CM, Yamashita M, Hatziioannou T, Bieniasz PD. 2013. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 502: 563-566. http://dx.doi.org/10.1038/nature12653.
18. Goujon C, Moncorge O, Bauby H, Doyle T, Ward CC, Schaller T, Hue S, Barclay WS, Schulz R, Malim MH. 2013. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature 502:559-562. http://dx.doi.org/10.1038/nature12542.
19. Lehmann C, Taubert D, Jung N, Fatkenheuer G, van Lunzen J, Hartmann P, Romerio F. 2009. Preferential upregulation of interferon-alpha subtype 2 expression in HIV-1 patients. AIDS Res Hum Retroviruses 25: 577-581. http://dx.doi.org/10.1089/aid.2008.0238.
20. Hardy GA, Sieg S, Rodriguez B, Anthony D, Asaad R, Jiang W, Mudd J, Schacker T, Funderburg NT, Pilch-Cooper HA, Debernardo R, Rabin RL, Lederman MM, Harding CV. 2013. Interferon-alpha is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS One 8:e56527. http://dx.doi.org/10.1371/journal.pone.0056527.
21. Fraietta JA, Mueller YM, Yang G, Boesteanu AC, Gracias DT, Do DH, Hope JL, Kathuria N, McGettigan SE, Lewis MG, Giavedoni LD, Jacobson JM, Katsikis PD. 2013. Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection. PLoS Pathog 9:e1003658. http://dx.doi.org/10.1371/journal.ppat.1003658.
22. Doyle T, Goujon C, Malim MH. 2015. HIV-1 and interferons: who's interfering with whom? Nat Rev Microbiol 13:403-413. http://dx.doi.org/10.1038/nrmicro3449.
23. Moron-Lopez S, Gomez-Mora E, Salgado M, Ouchi D, Puertas MC, Urrea V, Navarro J, Jou A, Perez M, Tural C, Clotet B, Montaner LJ, Blanco J, Crespo M, Martinez-Picado J. 2016. Short-term treatment with IFNalpha diminishes expression of HIV-1 and reduces CD4+ T-cell activation in HIV/HCV-coinfected patients on antiretroviral therapy. J Infect Dis 213:1008-1012. http://dx.doi.org/10.1093/infdis/jiv521.
24. Abdel-Mohsen M, Deng X, Liegler T, Guatelli JC, Salama MS, Ghanem Hel D, Rauch A, Ledergerber B, Deeks SG, Gunthard HF, Wong JK, Pillai SK. 2014. Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo. J Virol 88:763-767. http://dx.doi.org/10.1128/JVI.02687-13.
25. Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB, AIDS Clinical Trials Group A5192 Team. 2010. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis 201:1686-1696. http://dx.doi.org/10.1086/652420.
26. Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, Busch MP, Deeks SG, Carrington M, O'Doherty U, Kostman J, Montaner LJ. 2013. Pegylated interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis 207:213-222. http://dx.doi.org/10.1093/infdis/jis663.
27. Brockmeyer NH, Poffhoff A, Bader A, Hochdorfer B, Schlottmann R, Rasokat H, Altmeyer P, Kreuter A. 2006. Treatment of condylomata acuminata with pegylated interferon alfa-2b in HIV-infected patients. Eur J Med Res 11:27-32.
28. Dianzani F, Rozera G, Abbate I, D'Offizi G, Abdeddaim A, Vlassi C, Antonucci G, Narciso P, Martini F, Capobianchi MR. 2008. Interferon may prevent HIV viral rebound after HAART interruption in HIV patients. J Interferon Cytokine Res 28:1-3. http://dx.doi.org/10.1089/jir.2007.0076.
29. Frissen PH, de Wolf F, Reiss P, Bakker PJ, Veenhof CH, Danner SA, Goudsmit J, Lange JM. 1997. High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma. J Infect Dis 176:811-814. http://dx.doi.org/10.1086/517309.
30. Haas DW, Lavelle J, Nadler JP, Greenberg SB, Frame P, Mustafa N, St Clair M, McKinnis R, Dix L, Elkins M, Rooney J. 2000. A randomized trial of interferon alpha therapy for HIV type 1 infection. AIDS Res Hum Retroviruses 16:183-190. http://dx.doi.org/10.1089/088922200309278.
31. Tavel JA, Huang CY, Shen J, Metcalf JA, Dewar R, Shah A, Vasudevachari MB, Follmann DA, Herpin B, Davey RT, Polis MA, Kovacs J, Masur H, Lane HC. 2010. Interferon-alpha produces significant decreases in HIV load. J Interferon Cytokine Res 30:461-464. http://dx.doi.org/10.1089/jir.2009.0090.
32. Fernandez-Cruz E, Lang JM, Frissen J, Furner V, Chateauvert M, Boucher CA, Dowd P, Stevens J. 1995. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+cell counts>150 x 10(6)/L: results of the Zidon trial. Zidon Study Group. AIDS 9:1025-1035.
33. Krown SE, Aeppli D, Balfour HH, Jr. 1999. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team. J Acquir Immune Defic Syndr Hum Retrovirol 20:245-254. http://dx.doi.org/10.1097/00042560-199903010-00005.
34. Boue F, Reynes J, Rouzioux C, Emilie D, Souala F, Tubiana R, Goujard C, Lancar R, Costagliola D. 2011. Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial. AIDS 25:115-118. http://dx.doi.org/10.1097/QAD.0b013e328340a1e7.
35. Sun H, Buzon MJ, Shaw A, Berg RK, Yu XG, Ferrando-Martinez S, Leal M, Ruiz-Mateos E, Lichterfeld M. 2014. Hepatitis C therapy with interferon-alpha and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients. J Infect Dis 209:1315-1320. http://dx.doi.org/10.1093/infdis/jit628.
36. Kumaran J, Wei L, Kotra LP, Fish EN. 2007. A structural basis for interferon-alpha-receptor interactions. FASEB J 21:3288-3296. http://dx.doi.org/10.1096/fj.07-8585com.
37. Lavender KJ, Pang WW, Messer RJ, Duley AK, Race B, Phillips K, Scott D, Peterson KE, Chan CK, Dittmer U, Dudek T, Allen TM, Weissman IL, Hasenkrug KJ. 2013. BLT-humanized C57BL/6 Rag2-/-gammac-/-CD47-/-mice are resistant to GVHD and develop B-and T-cell immunity to HIV infection. Blood 122:4013-4020. http://dx.doi.org/10.1182/blood-2013-06-506949.
38. Lavender KJ, Messer RJ, Race B, Hasenkrug KJ. 2014. Production of bone marrow, liver, thymus (BLT) humanized mice on the C57BL/6 Rag2(-/-)gammac(-/-)CD47(-/-) background. J Immunol Methods 407: 127-134. http://dx.doi.org/10.1016/j.jim.2014.04.008.
39. Kalie E, Jaitin DA, Abramovich R, Schreiber G. 2007. An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J Biol Chem 282:11602-11611. http://dx.doi.org/10.1074/jbc.M610115200.
40. Zimmermann A, Trilling M, Wagner M, Wilborn M, Bubic I, Jonjic S, Koszinowski U, Hengel H. 2005. A cytomegaloviral protein reveals a dual role for STAT2 in IFN-{gamma} signaling and antiviral responses. J Exp Med 201:1543-1553. http://dx.doi.org/10.1084/jem.20041401.
41. Schindler M, Munch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, Muller-Trutwin MC, Novembre FJ, Peeters M, Courgnaud V, Bailes E, Roques P, Sodora DL, Silvestri G, Sharp PM, Hahn BH, Kirchhoff F. 2006. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 125:1055-1067. http://dx.doi.org/10.1016/j.cell.2006.04.033.
42. Papkalla A, Munch J, Otto C, Kirchhoff F. 2002. Nef enhances human immunodeficiency virus type 1 infectivity and replication independently of viral coreceptor tropism. J Virol 76:8455-8459. http://dx.doi.org/10.1128/JVI.76.16.8455-8459.2002.
43. Dillon SM, Manuzak JA, Leone AK, Lee EJ, Rogers LM, McCarter MD, Wilson CC. 2012. HIV-1 infection of human intestinal lamina propria CD4+ T cells in vitro is enhanced by exposure to commensal Escherichia coli. J Immunol 189:885-896. http://dx.doi.org/10.4049/jimmunol.1200681.
44. Steele AK, Lee EJ, Manuzak JA, Dillon SM, Beckham JD, McCarter MD, Santiago ML, Wilson CC. 2014. Microbial exposure alters HIV-1-induced mucosal CD4+ T cell death pathways ex vivo. Retrovirology 11:14. http://dx.doi.org/10.1186/1742-4690-11-14.
45. Fenton-May AE, Dibben O, Emmerich T, Ding H, Pfafferott K, Aasa-Chapman MM, Pellegrino P, Williams I, Cohen MS, Gao F, Shaw GM, Hahn BH, Ochsenbauer C, Kappes JC, Borrow P. 2013. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology 10:146. http://dx.doi.org/10.1186/1742-4690-10-146.
46. Daud A, Soon C, Dummer R, Eggermont AM, Hwu WJ, Grob JJ, Garbe C, Hauschild A. 2012. Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opin Biol Ther 12:1087-1099. http://dx.doi.org/10.1517/14712598.2012.694421.
47. Payne MJ, Argyropoulou K, Lorigan P, McAleer JJ, Farrugia D, Davidson N, Kelly C, Chao D, Marshall E, Han C, Wellman S, Middleton MR. 2014. Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J Clin Oncol 32:185-190. http://dx.doi.org/10.1200/JCO.2013.49.8717.
48. Reagan-Shaw S, Nihal M, Ahmad N. 2008. Dose translation from animal to human studies revisited. FASEB J 22:659-661.
49. Malnati MS, Scarlatti G, Gatto F, Salvatori F, Cassina G, Rutigliano T, Volpi R, Lusso P. 2008. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat Protoc 3:1240-1248. http://dx.doi.org/10.1038/nprot.2008.108.
50. Butchi NB, Woods T, Du M, Morgan TW, Peterson KE. 2011. TLR7 and TLR9 trigger distinct neuroinflammatory responses in the CNS. Am J Pathol 179:783-794. http://dx.doi.org/10.1016/j.ajpath.2011.04.011.
51. Halemano K, Guo K, Heilman KJ, Barrett BS, Smith DS, Hasenkrug KJ, Santiago ML. 2014. Immunoglobulin somatic hypermutation by APOBEC3/Rfv3 during retroviral infection. Proc Natl Acad Sci U S A 111: 7759-7764. http://dx.doi.org/10.1073/pnas.1403361111.
52. Barrett BS, Guo K, Harper MS, Li SX, Heilman KJ, Davidson NO, Santiago ML. 2014. Reassessment of murine APOBEC1 as a retrovirus restriction factor in vivo. Virology 468-470:601-608. http://dx.doi.org/10.1016/j.virol.2014.09.006.
53. Pestka S. 2007. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 282:20047-20051. http://dx.doi.org/10.1074/jbc.R700004200.
54. Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, Levin D, Wijeyesinghe S, Makamdop KN, del Prete GQ, Hill BJ, Timmer JK, Reiss E, Yarden G, Darko S, Contijoch E, Todd JP, Silvestri G, Nason M, Norgren RB, Jr, Keele BF, Rao S, Langer JA, Lifson JD, Schreiber G, Douek DC. 2014. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511:601-605. http://dx.doi.org/10.1038/nature13554.
55. Rychert J, Strick D, Bazner S, Robinson J, Rosenberg E. 2010. Detection of HIV gp120 in plasma during early HIV infection is associated with increased proinflammatory and immunoregulatory cytokines. AIDS Res Hum Retroviruses 26:1139-1145. http://dx.doi.org/10.1089/aid.2009.0290.
56. Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht FM, Busch MP. 2006. Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV type 1 infection. AIDS Res Hum Retroviruses 22:757-762. http://dx.doi.org/10.1089/aid.2006.22.757.
57. Cocchi F, DeVico AL, Yarchoan R, Redfield R, Cleghorn F, Blattner WA, Garzino-Demo A, Colombini-Hatch S, Margolis D, Gallo RC. 2000. Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci U S A 97:13812-13817. http://dx.doi.org/10.1073/pnas.240469997.
58. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. 2005. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 174:4465-4469. http://dx.doi.org/10.4049/jimmunol.174.8.4465.
59. Schneider WM, Chevillotte MD, Rice CM. 2014. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32:513-545. http://dx.doi.org/10.1146/annurev-immunol-032713-120231.
60. Harper MS, Barrett BS, Smith DS, Li SX, Gibbert K, Dittmer U, Hasenkrug KJ, Santiago ML. 2013. IFN-alpha treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3. J Immunol 190:1583-1590. http://dx.doi.org/10.4049/jimmunol.1202920.
61. Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, Neuberger MS. 2004. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol 337:585-596. http://dx.doi.org/10.1016/j.jmb.2004.01.046.
62. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430. http://dx.doi.org/10.1038/nature06553.
63. Alvarez RA, Hamlin RE, Monroe A, Moldt B, Hotta MT, Rodriguez Caprio G, Fierer DS, Simon V, Chen BK. 2014. HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J Virol 88:6031-6046. http://dx.doi.org/10.1128/JVI.00449-14.
64. Li SX, Barrett BS, Heilman KJ, Messer RJ, Liberatore RA, Bieniasz PD, Kassiotis G, Hasenkrug KJ, Santiago ML. 2014. Tetherin promotes the innate and adaptive cell-mediated immune response against retrovirus infection in vivo. J Immunol 193:306-316. http://dx.doi.org/10.4049/jimmunol.1400490.
65. Stegmann KA, Bjorkstrom NK, Veber H, Ciesek S, Riese P, Wiegand J, Hadem J, Suneetha PV, Jaroszewicz J, Wang C, Schlaphoff V, Fytili P, Cornberg M, Manns MP, Geffers R, Pietschmann T, Guzman CA, Ljunggren HG, Wedemeyer H. 2010. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 138:1885-1897. http://dx.doi.org/10.1053/j.gastro.2010.01.051.
66. Jost S, Altfeld M. 2013. Control of human viral infections by natural killer cells. Annu Rev Immunol 31:163-194. http://dx.doi.org/10.1146/annurev-immunol-032712-100001.
67. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. 2003. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112. http://dx.doi.org/10.1126/science.1083338.
68. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650. http://dx.doi.org/10.1038/nature00939.
69. Harris RS, Sheehy AM, Craig HM, Malim MH, Neuberger MS. 2003. DNAdeamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nat Immunol 4:641-643. http://dx.doi.org/10.1038/ni0703-641.
70. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103. http://dx.doi.org/10.1038/nature01709.
71. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98. http://dx.doi.org/10.1038/nature01707.
72. Krisko JF, Martinez-Torres F, Foster JL, Garcia JV. 2013. HIV restriction by APOBEC3 in humanized mice. PLoS Pathog 9:e1003242. http://dx.doi.org/10.1371/journal.ppat.1003242.
73. Cha L, Berry CM, Nolan D, Castley A, Fernandez S, French MA. 2014. Interferon-alpha, immune activation and immune dysfunction in treated HIV infection. Clin Transl Immunology 3:e10. http://dx.doi.org/10.1038/cti.2014.1.
74. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, Sahagan BG, Neote K. 1998. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187:2009-2021. http://dx.doi.org/10.1084/jem.187.12.2009.
75. Zeremski M, Dimova RB, Benjamin S, Penney MS, Botfield MC, Talal AH. 2015. Intrahepatic and peripheral CXCL10 expression in hepatitis C virus-infected patients treated with telaprevir, pegylated interferon, and ribavirin. J Infect Dis 211:1795-1799. http://dx.doi.org/10.1093/infdis/jiu807.
76. Foley JF, Yu CR, Solow R, Yacobucci M, Peden KW, Farber JM. 2005. Roles for CXC chemokine ligands 10 and 11 in recruiting CD4+ T cells to HIV-1-infected monocyte-derived macrophages, dendritic cells, and lymph nodes. J Immunol 174:4892-4900. http://dx.doi.org/10.4049/jimmunol.174.8.4892.
77. Gray CM, Hong HA, Young K, Lewis DA, Fallows D, Manca C, Kaplan G. 2013. Plasma interferon-gamma-inducible protein 10 can be used to predict viral load in HIV-1-infected individuals. J Acquir Immune Defic Syndr 63:e115-e116. http://dx.doi.org/10.1097/QAI.0b013e3182930ea8.
78. Jiao Y, Zhang T, Wang R, Zhang H, Huang X, Yin J, Zhang L, Xu X, Wu H. 2012. Plasma IP-10 is associated with rapid disease progression in early HIV-1 infection. Viral Immunol 25:333-337. http://dx.doi.org/10.1089/vim.2012.0011.
79. Bosinger SE, Li Q, Gordon SN, Klatt NR, Duan L, Xu L, Francella N, Sidahmed A, Smith AJ, Cramer EM, Zeng M, Masopust D, Carlis JV, Ran L, Vanderford TH, Paiardini M, Isett RB, Baldwin DA, Else JG, Staprans SI, Silvestri G, Haase AT, Kelvin DJ. 2009. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 119:3556-3572. http://dx.doi.org/10.1172/JCI40115.
80. Vanderford TH, Slichter C, Rogers KA, Lawson BO, Obaede R, Else J, Villinger F, Bosinger SE, Silvestri G. 2012. Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation. Blood 119:5750-5757. http://dx.doi.org/10.1182/blood-2012-02-411496.
81. Jacquelin B, Petitjean G, Kunkel D, Liovat AS, Jochems SP, Rogers KA, Ploquin MJ, Madec Y, Barre-Sinoussi F, Dereuddre-Bosquet N, Lebon P, Le Grand R, Villinger F, Muller-Trutwin M. 2014. Innate immune responses and rapid control of inflammation in African green monkeys treated or not with interferon-alpha during primary SIVagm infection. PLoS Pathog 10:e1004241. http://dx.doi.org/10.1371/journal.ppat.1004241.
82. Vazquez N, Schmeisser H, Dolan MA, Bekisz J, Zoon KC, Wahl SM. 2011. Structural variants of IFNalpha preferentially promote antiviral functions. Blood 118:2567-2577. http://dx.doi.org/10.1182/blood-2010-12-325027.
83. Villinger F, Brar SS, Mayne A, Chikkala N, Ansari AA. 1995. Comparative sequence analysis of cytokine genes from human and nonhuman primates. J Immunol 155:3946-3954.
84. Ng CT, Sullivan BM, Teijaro JR, Lee AM, Welch M, Rice S, Sheehan KC, Schreiber RD, Oldstone MB. 2015. Blockade of interferon beta, but not interferon alpha, signaling controls persistent viral infection. Cell Host Microbe 17:653-661. http://dx.doi.org/10.1016/j.chom.2015.04.005.
85. Chen Q, Khoury M, Chen J. 2009. Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proc Natl Acad Sci U S A 106:21783-21788. http://dx.doi.org/10.1073/pnas.0912274106.
86. Huang JJ, Newton RC, Rutledge SJ, Horuk R, Matthew JB, Covington M, Lin Y. 1988. Characterization of murine IL-1 beta. Isolation, expression, and purification. J Immunol 140:3838-3843.